NCT06690697View on ClinicalTrials.gov

Combination of Toripalimab and JS004 Therapy for ccRCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Clear Cell Renal Cell Carcinoma
Interventions
DRUG

JS004

200 mg, ivdrip, D1, Q3W, each 21 days as a treatment cycle

DRUG

Toripalimab

240 mg, ivdrip, D1, Q3W, each 21 days as a treatment cycle

DRUG

Axitinib

5 mg, po, bid, each 21 days as a treatment cycle

DRUG

Sorafenib

0.4 g, po, bid, each 21 days as a treatment cycle

Trial Locations (1)

Unknown

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER